NYSEAMERICAN:BPMX - Biopharmx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biopharmx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.36 -0.01 (-2.67 %) (As of 02/20/2020 01:33 PM ET) Add Compare Today's Range$0.36Now: $0.37▼$0.3950-Day Range$0.31MA: $0.35▼$0.3952-Week Range$0.26Now: $0.37▼$4.46Volume489,789 shsAverage Volume1.95 million shsMarket Capitalization$5.18 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Read More… Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CUSIPN/A CIKN/A Webhttp://www.biopharmx.com/ Phone+1-650-8895020Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees17 Outstanding Shares14,187,000Market Cap$5.18 million Next Earnings Date3/12/2020 (Estimated) OptionableNot Optionable Receive BPMX News and Ratings via Email Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter. AMEX:BPMX Rates by TradingView Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions What is Biopharmx's stock symbol? Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX." When did Biopharmx's stock split? How did Biopharmx's stock split work? Shares of Biopharmx reverse split on Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split. How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) posted its earnings results on Tuesday, December, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.08. View Biopharmx's Earnings History. When is Biopharmx's next earnings date? Biopharmx is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Biopharmx. What price target have analysts set for BPMX? 1 Wall Street analysts have issued 1 year price objectives for Biopharmx's stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Biopharmx's stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 174.0% from the stock's current price. View Analyst Price Targets for Biopharmx. What is the consensus analysts' recommendation for Biopharmx? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biopharmx. Has Biopharmx been receiving favorable news coverage? Press coverage about BPMX stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biopharmx earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Biopharmx. Who are some of Biopharmx's key competitors? Some companies that are related to Biopharmx include Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Crescita Therapeutics (CTX), Prescient Therapeutics (PTX), Kane Biotech (KNE), Regeneus (RGS), Fusion Antibodies (FAB), Agronomics (ANIC), Quest PharmaTech (QPT), BTC Health (BTC), biOasis Technologies (BTI), Adalta (1AD), Briacell Therapeutics (BCT), ContraVir Pharmaceuticals (HEPA) and e-Therapeutics (ETX). What other stocks do shareholders of Biopharmx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN). Who are Biopharmx's key executives? Biopharmx's management team includes the folowing people: Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)Dr. José Zayas, Sr. VP of OperationsMs. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs Who are Biopharmx's major shareholders? Biopharmx's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Barclays PLC (0.86%) and Virtu Financial LLC (0.45%). Company insiders that own Biopharmx stock include Anja B Krammer, David S Tierney, Stephen Morlock and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Biopharmx. Which institutional investors are selling Biopharmx stock? BPMX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Virtu Financial LLC. View Insider Buying and Selling for Biopharmx. How do I buy shares of Biopharmx? Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Biopharmx's stock price today? One share of BPMX stock can currently be purchased for approximately $0.37. How big of a company is Biopharmx? Biopharmx has a market capitalization of $5.18 million. Biopharmx employs 17 workers across the globe.View Additional Information About Biopharmx. What is Biopharmx's official website? The official website for Biopharmx is http://www.biopharmx.com/. How can I contact Biopharmx? Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020. MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 294 (Vote Outperform)Underperform Votes: 185 (Vote Underperform)Total Votes: 479MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: What is a recession?
